Fig. 1: MIR31HG is overexpressed in tumor tissues and inversely related to the clinical prognosis of NSCLC patients.

A Kaplan–Meier survival analysis of overall and progress-free survival in NSCLC patients according to lncRNA MIR31HG expression. NSCLC non-small cell lung cancer. B MIR31HG expression in LUAD and LUSC tumor tissues and normal tissues extracted from the GEPIA database. LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma. C MIR31HG expression in NSCLC tumor tissues from patients at different clinical stages plotted by the GEPIA database. D In situ hybridization staining of MIR31HG in 60 paired NSCLC tissues and adjacent non-cancerous tissues (upper panel). Scale bar, 100 µm. Quantification of MIR31HG expression levels between cancer and adjacent non-cancerous tissues (lower panel). E MIR31HG transcription levels in 15 paired NSCLC tissues and adjacent non-cancerous tissues detected by RT-PCR. F MIR31HG transcription levels in the peripheral serum of 114 healthy populations and 115 lung cancer patients measured by RT-PCR. All of samples were normalized to the healthy 1# peripheral serum and the comparison of significant differences was performed by grouped student’s t-test. G MIR31HG, CD34, CD44, and CD133 transcription levels in NSCLC parental and stem cell spheroids detected by RT-qPCR. Data are presented as mean ± SEM; significance abundance: *p < 0.05, **p < 0.01, ***p < 0.001.